Search

News Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Ankylosing Spondylitis: Network Meta-Analysis

A literature review and network meta-analysis of randomized controlled trials published in the journal Experimental and Therapeutic Medicine demonstrates the high efficacy and good tolerability of 6 non-steroidal anti-inflammatory drugs (NSAIDs) including etoricoxib, celecoxib, meloxicam, diclofenac, naproxen, and ß-D-mannuronic acid in the treatment of ankylosing spondylitis (AS).

Source: Updates in Pain Treatment 30. 3. 2023

News Brentuximab Vedotin and Relapsing/Refractory NHL with High Expression of CD30

A recently published study by authors from South Korea focused on examining the efficacy of brentuximab vedotin in patients with non-Hodgkin lymphomas (NHL) that highly express CD30 (i.e., > 30% CD30-positive tumor cells based on immunohistochemistry), where the disease had relapsed or was refractory to previous treatments.

Source: Hematologic Malignancies 7. 10. 2020

News Protection of Ovarian Function During Breast Cancer Treatment

Women diagnosed with breast cancer of childbearing age are concerned about how to maintain ovarian function even after undergoing chemotherapy. Therefore, a team of doctors from the United Kingdom focused on the gonadotropin-releasing hormone agonist and its ability to protect women from premature menopause after chemotherapy.

Source: Oncological Treatment 20. 12. 2021

News Trazodone in the Treatment of Depressive Disorder –⁠ A Case Study

Presented by MUDr. Sylva Racková, Ph.D. Psychiatric Clinic, Plzeň

Source: Depression and Anxiety 12. 2. 2021

News Bilastine and its role in the treatment of allergic rhinoconjunctivitis and urticaria in children

The prevalence of allergic rhinitis (AR) in the pediatric population is estimated worldwide at 10-20%. The efficacy and safety of bilastine (a second-generation antihistamine) in adult patients and adolescents have already been proven in clinical studies. Below we summarize experiences with its use in children under 12 years of age.

Source: Allergic Reactions 10. 6. 2022

News “Think about the thyroid gland during pregnancy,” reminds awareness campaign

Thyroid disorders can endanger the health of both the fetus and the mother. Sometimes, however, the problem only manifests during pregnancy, and the expectant mother or her doctor might not notice it amidst other ongoing changes. The issue was highlighted by an event called “Thyroid Week,” which took place in the Czech Republic during the last week of May 2020.

Source: Thyroid Disorders 10. 6. 2020

News Li-Fraumeni Syndrome –⁠ Indication for Testing and Recommended Surveillance

A germline mutation of the TP53 gene, which causes Li-Fraumeni syndrome, results in a congenital predisposition to the occurrence of malignant tumors, such as pediatric malignancies, breast cancer, bone sarcomas, and others. We bring a summary of indications for testing the pathogenic variant of the TP53 gene according to the recommendations of the National Comprehensive Cancer Network (NCCN) and the surveillance program for carriers of this variant according to the consensus of the current recommendations of the European, American, Japanese, and Australian scientific societies compared to the recommendations of the Czech Oncology Society ČLS JEP.

Source: Genetics 3. 5. 2023

News Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria

Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and their incidence continues to rise. The study presented below investigated the efficacy of therapy with the combination of ceftazidime/avibactam (a third-generation cephalosporin and a beta-lactamase inhibitor) in treating these infections compared to the 'best available antibiotic therapy' (BAT).

Source: Anti-Infectives 22. 8. 2023

News ESC 2022: How to use gliflozins in heart failure? American guidelines now also consider the EMPEROR-Preserved study

One of the important current cardiology topics is the possibility of using gliflozins in patients with chronic heart failure (HF) regardless of the left ventricular ejection fraction (LVEF). The possibilities of introducing these medicines into clinical practice, considering the issue in international guidelines, and the results of empagliflozin in recent studies were covered in a practically oriented symposium as part of the professional program of this year's European Society of Cardiology Congress (ESC 2022).

Source: Heart Failure 13. 10. 2022

News Substitution Treatment of von Willebrand Disease with vWF and FVIII Concentrates

Recently published recommendations from Poland regarding the diagnosis and treatment of von Willebrand disease (vWD) provide a comprehensive summary of the current approach to substitution therapy using concentrates containing von Willebrand factor (vWF) and coagulation factor VIII (FVIII), administered primarily during bleeding or surgical procedures.

Source: Von Willebrand Disease 29. 11. 2022

Články časopisu Role of the transforming growth factor (TGF)-β signal pathway in haematopoiesis and studies of new inhibitors of this pathway in the treatment of lower-risk myelodysplastic syndrome

Author of the article: O. Fuchs, R. Bokorová Source: Transfuze a hematologie dnes | 4/2019 8. 11. 2019

News Vitamins in Prevention and Treatment of COVID-19

Vitamin supplementation is an important part of therapy for various diseases, and it seems that they also play a significant role in the case of COVID-19. What kind of role? It's certainly not a panacea, but it's not something to be underestimated.

Source: Parenteral Nutrition 7. 6. 2021

News Trazodone with Extended Release Improves Patient Compliance

Since 2015, the antidepressant trazodone is available in the Czech Republic in a controlled-release formulation. A sufficiently high plasma level for 24 hours without fluctuation allows for administration only once a day, while eliminating side effects.

Source: Depression and Anxiety 20. 5. 2020

News Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia

Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years. Their administration represents a new approach compared to the previous, long-established treatment, and has significantly changed the prognosis of the disease in many patients.

Source: Immune Thrombocytopenia 9. 4. 2022

News Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP

What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of patients with immune thrombocytopenia (ITP)? Italian authors conducted a survey using the Delphi method among selected experts to gather answers to this question and recommendations for clinical practice. Here, we briefly summarize the key points of their consensus published last year.

Source: Immune Thrombocytopenia 10. 8. 2022